Combination of CDNF and Deep Brain Stimulation Decreases Neurological Deficits in Late-stage Model Parkinson’s Disease
Open Access
- 1 March 2018
- journal article
- research article
- Published by Elsevier in Neuroscience
- Vol. 374, 250-263
Abstract
No abstract availableKeywords
Funding Information
- Finnish Government
- Finnish Parkinson Foundation (#25027, #256398, #277910)
This publication has 74 references indexed in Scilit:
- AAV2-mediated striatum delivery of human CDNF prevents the deterioration of midbrain dopamine neurons in a 6-hydroxydopamine induced parkinsonian rat modelExperimental Neurology, 2013
- Gene therapy with AAV2‐CDNF provides functional benefits in a rat model of Parkinson's diseaseBrain and Behavior, 2013
- High correlation between in vivo [123I]β-CIT SPECT/CT imaging and post-mortem immunohistochemical findings in the evaluation of lesions induced by 6-OHDA in ratsEJNMMI Research, 2013
- CDNF Protects the Nigrostriatal Dopamine System and Promotes Recovery after MPTP Treatment in MiceCell Transplantation, 2012
- Characterization of the Intracellular Localization, Processing, and Secretion of Two Glial Cell Line-Derived Neurotrophic Factor Splice IsoformsJournal of Neuroscience, 2010
- Stimulation of the rat subthalamic nucleus is neuroprotective following significant nigral dopamine neuron lossNeurobiology of Disease, 2010
- Network perspectives on the mechanisms of deep brain stimulationNeurobiology of Disease, 2010
- Mesencephalic Astrocyte-Derived Neurotrophic Factor Is Neurorestorative in Rat Model of Parkinson's DiseaseJournal of Neuroscience, 2009
- Postsynaptic Secretion of BDNF and NT-3 from Hippocampal Neurons Depends on Calcium–Calmodulin Kinase II Signaling and Proceeds via Delayed Fusion Pore OpeningThe Journal of Neuroscience, 2007
- Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivoNeuroscience Letters, 1994